Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT00769067
Official study title

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Study summary

This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedErlotinib and PF-00299804

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 7, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?59 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Pfizer
Interventions being studied
Drug: Erlotinib; Drug: PF-00299804
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • advanced measurable Non-Small Cell Lung Cancer (NSCLC);
  • progressed after 1-2 prior chemotherapy;
  • Eastern Cooperative Oncology Group (ECOG) 0-2;
  • tissue available for future KRAS/ EGFR testing
Reasons someone may not be able to joinExclusion criteria
  • prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;
  • active or untreated Central Nervous System (CNS) metastases;

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Northwest Alabama Cancer CenterMuscle Shoals, Alabama
  • Agajanian Institute of Oncology and HematologyMontebello, California
  • Bridgeport HospitalBridgeport, Connecticut
  • Wittingham Cancer Center @ Norwalk HospitalNorwalk, Connecticut
  • Medical Oncology & Hematology, P.C.Waterbury, Connecticut
  • Winship Cancer Institute at Grady Health SystemsAtlanta, Georgia
  • Winship Cancer Institute, Emory UniversityAtlanta, Georgia
  • Winship Cancer Institute at Emory UniversityAtlanta, Georgia
  • Winship Cancer Institute of Emory UniversityAtlanta, Georgia
  • Winship Cancer Institute, Emory UniversityAtlanta, Georgia
  • Augusta Oncology Associates, P.C.Augusta, Georgia
  • Augusta Oncology Associates, PCAugusta, Georgia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 7, 2015. Always confirm current availability with the study team.

View original record ↗